PRODUCT INFORMATION



CD4 Chimeric Monoclonal Antibody (Clone CE9.1)

Item No. 37160

Overview and Properties

Contents: Synonyms:	This vial contains 200 μ g of protein A-affinity purified monoclonal antibody Cluster of Differentiation 4, T Cell Surface Antigen T4, T Cell Surface Glycoprotein CD4
Immunogen:	Recombinant human CD4
Cross Reactivity:	(+) CD4
Species Reactivity:	(+) Human, chimpanzee
Uniprot No.:	P01730
Form:	Liquid
Storage:	-20°C (as supplied)
Stability:	≥1 year
Storage Buffer:	PBS with 0.02% ProClin [™] 300
Clone:	CE9.1 (Clenoliximab)
Host:	This antibody is composed of a fusion of the antigen-binding domain of a primate anti-
	CD4 monoclonal antibody with the constant domain of human $IgG4\lambda$.
Isotype:	lgG4
Applications:	ELISA, Flow cytometry (FC), and Immunohistochemistry (IHC); the optimal working concentration/dilution should be determined empirically.

Images



WB using CD4 Chimeric Monoclonal Antibody (Clone CE9.1). Human thyroid tumor samples were resolved on a 15% SDS PAGE gel and blots probed with CD4 Chimeric Monoclonal Antibody (Clone CE9.1) at 1.5 μ g/ml before detection using an anti-human IgG4 secondary antibody. Protein was detected by chemiluminescence. The expected unmodified running size for CD4 is 51kDa. Here, some non-specific bands can also be seen. WB using CD4 Chimeric Monoclonal Antibody (Clone CE9.1) successfully detected CD4 in human thyroid tissue samples.



Immunohistochemical (IHC) staining of guinea pig skin using CD4 Chimeric Monoclonal Antibody (Clone CE9.1). Anti-CD4 staining of formalin-fixed paraffin-embedded guinea pig skin tissue, at 40x magnification. CD4 Chimeric Monoclonal Antibody (Clone CE9.1) was used to stain samples at a concentration of 3 µg/ml.

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

CD4 is a type I transmembrane glycoprotein that functions as a T cell receptor (TCR) co-receptor.¹ It exists as a single polypeptide chain composed of four extracellular immunoglobulin-like (Ig-like) domains that interact with MHC class II molecules, a transmembrane domain, and a cytoplasmic tail that associates with the tyrosine kinase LCK and mediates signal transduction to the TCR, which is essential for T cell activation.² It is expressed on the surface of, and used as a marker for, T cells, and its expression is used to characterize the development stage of thymocytes. Upon binding to antigen-displaying MHC class II molecules expressed by antigen-presenting cells (APCs), naïve CD4⁺ T cells differentiate and proliferate in a cytokine-dependent manner into a variety of T helper (Th) cell subsets, including Th1, Th2, and Th17 cells, which enhance and direct innate and adaptive immune cell responses to numerous pathogens and have additional roles in cancer, asthma and allergy, and autoimmunity.^{3,4} CD4 is also the receptor for HIV attachment and entry into cells, resulting in depletion of CD4⁺ cells in patients infected with HIV.^{5.6} Cayman's CD4 Chimeric Monoclonal Antibody (Clone CE9.1) was produced recombinantly from the original CE9.1 antibody sequence and can be used for ELISA, flow cytometry (FC), and immunohistochemistry (IHC) applications. The CE9.1 antibody was generated by fusing IgG4 λ constant domains to the antigen-binding domain of a primate anti-CD4 monoclonal antibody.⁷

References

- 1. Wittlich, M., Koenig, B.W., Hoffmann, S., *et al.* Structural characterization of the transmembrane and cytoplasmic domains of human CD4. *Biochim. Biophys. Acta* **1768(12)**, 2949-2960 (2007).
- Mak, T.W. and Saunders, M.E. The T cell receptor: Structure of its proteins and genes. The immune response: Basic and clinical principles. Picknett, T. and Lebedeva, V., editors, 1st edition, Elsevier Academic Press (2006).
- 3. Nguyen, Q.P., Deng, T.Z., Witherden, D.A., *et al.* Origins of CD4⁺ circulating and tissue-resident memory T-cells. *Immunology* **157(1)**, 3-12 (2019).
- 4. Zhu, J. and Paul, W.E. CD4 T cells: Fates, functions, and faults. Blood 112(5), 1557-1569 (2008).
- 5. Wilen, C.B., Tilton, J.C., and Doms, R.W. HIV: Cell binding and entry. *Cold Spring Harb. Perspect. Med.* **2(8)**, a006866 (2012).
- Vijayan, K.K.V., Karthigeyan, K.P., Tripathi, S.P., et al. Pathophysiology of CD4+ T-cell depletion in HIV-1 and HIV-2 infections. Front. Immunol. 8, 580 (2017).
- Newman, R., Alberts, J., Anderson, D., *et al.* "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4. *Biotechnology (N.Y.)* 10(11), 1455-1460 (1992).

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM